Share This Article:

Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation

Abstract Full-Text HTML XML Download Download as PDF (Size:680KB) PP. 1214-1222
DOI: 10.4236/jct.2015.615132    3,082 Downloads   3,598 Views  

ABSTRACT

We conducted a phase II study of combination chemotherapy with carboplatin (Cb) and pemetrexed (Pem) followed by gefitinib (Gef) to determine the effects and toxicities in patients with non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutation. Eligible patients received four courses of Cb at a dose corresponding to a target area under the curve equal to 6 mg/mL·min and 500 mg/m2 Pem on day 1 every three to four weeks followed by sequential Gef 250 mg once a day until tumor progression. Sixteen of registered 28 patients responded to Cb and Pem combination. Twenty-seven patients received sequential Gef and 8 non-responders to Cb and Pem achieved PR. The overall response rate was 85.7%. Among the major toxicities, grade 3 SGPT elevation, nausea and thrombosis were observed in 3, 3 and 1 patients, respectively, who received Cb and Pem, and grade 3 SGPT elevation and dry skin were observed in 5 and 1 patients, respectively, who received Gef. There was no febrile neutropenia and no treatment-related death. The median progression-free survival time was 19.1 months. Among 21 patients who were followed up for more than 2 years, 14 survived during that time. Cb and Pem followed by Gef maintenance are recommended for further evaluation for patients with metastatic NSCLC harboring sensitive EGFR mutation.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Manabe, S. , Oshita, F. , Murakami, S. , Kondo, T. , Saito, H. , Kaneko, T. and Yamada, K. (2015) Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation. Journal of Cancer Therapy, 6, 1214-1222. doi: 10.4236/jct.2015.615132.

References

[1] Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., Zhu, J. and Johnson, D.H. (2002) Eastern Cooperative Oncology Group. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 346, 92-98.
http://dx.doi.org/10.1056/NEJMoa011954
[2] Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R. and Johnson, D.H. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. New England Journal of Medicine, 355, 2542-2550.
http://dx.doi.org/10.1056/NEJMoa061884
[3] Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.P. and Baselga, J. (2003) Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer (The IDEAL 1 Trial). Journal of Clinical Oncology, 21, 2237-2246.
http://dx.doi.org/10.1200/JCO.2003.10.038
[4] Kris, M.G., Natale, R.B., Herbst, R.S., Lynch Jr, T.J., Prager, D., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, H., Sandler, A., Albain, K.S., Cella, D., Wolf, M.K., Averbuch, S.D., Ochs, J.J. and Kay, A.C. (2003) Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial. JAMA, 290, 2149-2158.
http://dx.doi.org/10.1001/jama.290.16.2149
[5] Miller, V.A., Kris, M.G., Shah, N., Patel, J., Azzoli, C., Gomez, J., Krug, L.M., Pao, W., Rizvi, N., Pizzo, B., Tyson, L., Venkatraman, E., Ben-Porat, L., Memoli, N., Zakowski, M., Rusch, V. and Heelan, R.T. (2004) Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22, 1103-1109.
http://dx.doi.org/10.1200/JCO.2004.08.158
[6] Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserla,t S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J. and Haber, D.A. (2004) Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 350, 2129-2139.
http://dx.doi.org/10.1056/NEJMoa040938
[7] Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E. and Meyerson, M. (2004) EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 304, 1497-1500.
http://dx.doi.org/10.1126/science.1099314
[8] Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A. and Fukuoka, M. (2009) Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 361, 947-957.
http://dx.doi.org/10.1056/NEJMoa0810699
[9] Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S. and Nukiwa, T. (2010) North-East Japan Study Group: Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. New England Journal of Medicine, 362, 2380-2388.
http://dx.doi.org/10.1056/NEJMoa0909530
[10] Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K. and Fukuoka, M. (2010) West Japan Oncology Group: Gefitinib versus Cisplatin plus Docetaxel in Patients with Non-Small-Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial. Lancet Oncology, 11, 121-128.
http://dx.doi.org/10.1016/S1470-2045(09)70364-X
[11] Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M. and Paz-Ares, L., Spanish Lung Cancer Group in Collaboration with Groupe Francais de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 13, 239-246.
http://dx.doi.org/10.1016/S1470-2045(11)70393-X
[12] Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L. and You, C. (2011) Erlotinib versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study. The Lancet Oncology, 12, 735-742.
http://dx.doi.org/10.1016/S1470-2045(11)70184-X
[13] Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J.S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K.P. and Gandara, D. (2008) Phase III Study Comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 3543-3551.
http://dx.doi.org/10.1200/JCO.2007.15.0375
[14] Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F.V., Schiller, J.H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., Bisset, D. and Rosell, R., CISCA (CISplatin versus CArboplatin) Meta-Analysis Group (2007) Cisplatin-versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-Analysis. Journal of the National Cancer Institute, 99, 847-857.
http://dx.doi.org/10.1093/jnci/djk196
[15] Jiang, J., Liang, X., Zhou, X., Huang, R. and Chu, Z. (2007) A Meta-Analysis of Randomized Controlled Trials Comparing Carboplatin-Based to Cisplatin-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer. Lung Cancer, 57, 348-358.
http://dx.doi.org/10.1016/j.lungcan.2007.03.014
[16] Gronberg, B.H., Bremnes, R.M., Flotten, O., Amundsen, T., Brunsvig, P.F., Hjelde, H.H., Kaasa, S., von Plessen, C., Stornes, F., Tollali, T., Wammer, F., Aasebo, U. and Sundstrom, S. (2009) Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed plus Carboplatin Compared with Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 27, 3217-3224.
http://dx.doi.org/10.1200/JCO.2008.20.9114
[17] Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C. and Gwyther, S.G. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute, 92, 205-216.
http://dx.doi.org/10.1093/jnci/92.3.205
[18] Simon, R. (1989) Optimal Two-Stage Designs for Phase II Clinical Trial. Controlled Clinical Trials, 10, 1-10.
http://dx.doi.org/10.1016/0197-2456(89)90015-9
[19] Inoue, A., Kobayashi, K., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Saijo, Y., Hagiwara, K., Morita, S. and Nukiwa, T., North-East Japan Study Group (2013) Updated Overall Survival Results from a Randomized Phase III Trial Comparing Gefitinib with Carboplatin-Paclitaxel for Chemo-Naive Non-Small Cell Lung Cancer with Sensitive EGFR Gene Mutations (NEJ002). Annals of Oncology, 24, 54-59.
http://dx.doi.org/10.1093/annonc/mds214
[20] Sugawara, S., Oizumi, S., Minato, K., Harada, T., Inoue, A., Fujita, Y., Maemondo, M., Yoshizawa, H., Ito, K., Gemma, A., Nishitsuji, M., Harada, M., Isobe, H., Kinoshita, I., Morita, S., Kobayashi, K., Hagiwara, K., Kurihara, M. and Nukiwa, T., on behalf of North East Japan Study Group and Tokyo Cooperative Oncology Group (2015) Randomized Phase II Study of Concurrent versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer with Sensitive EGFR Mutations: NEJ005/TCOG0902. Annals of Oncology, 26, 888-894.
http://dx.doi.org/10.1093/annonc/mdv063
[21] Ohe, Y., Ohashi, Y., Kubota, K., Tamura, T., Nakagawa, K., Negoro, S., Nishiwaki, Y., Saijo, N., Ariyoshi, Y. and Fukuoka, M. (2007) Randomized Phase III Study of Cisplatin plus Irinotecan versus Carboplatin plus Paclitaxel, Cisplatin plus Gemcitabine, and Cisplatin plus Vinorelbine for Advanced Non-Small-Cell Lung Cancer: Four-Arm Cooperative Study in Japan. Annals of Oncology, 18, 317-323.
http://dx.doi.org/10.1093/annonc/mdl377

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.